Boothbay Fund Management, LLC Uni Qure N.V. Call Options Transaction History

Boothbay Fund Management, LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$3.78 - $10.12 $1.55 Million - $4.14 Million	-409,000 Reduced 92.85%	31,500 $155,000
Q2 2024 Aug 14, 2024	BUY	$4.39 - $5.43 $1.68 Million - $2.07 Million	382,000 Added 652.99%	440,500 $1.97 Million
Q1 2024 May 15, 2024	BUY	$4.82 - $6.93 $281,970 - $405,405	58,500 New	58,500 $304,000
Q2 2023 Aug 14, 2023	BUY	$11.12 - $22.2 $6.78 Million - $13.5 Million	609,400 New	609,400 $6.98 Million

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $266M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.